SPOTLIGHT: CytRx reviews toxicology data

Last week the FDA halted CytRx Phase II trial of a drug for Lou Gehrig's disease in order to analyze results from animal studies of arimoclomol. The FDA has clarified its decision and CytRx is now analyzing data from the previously completed toxicology study to prepare a response to the issues cited by the FDA. Release